Aztreonam + Avibactam injection is a combination of a monobactam β-lactam antibiotic and a β-lactamase inhibitor. The combination is particularly important when discussing difficult-to-treat Gram-negative bacteria and resistance mechanisms involving metallo-β-lactamases (MBLs) together with other β-lactamases.
Aztreonam and avibactam have different but complementary roles. Aztreonam provides the antibacterial activity, while avibactam inhibits several susceptible β-lactamases that can otherwise compromise the activity of aztreonam.
What Is Aztreonam Avibactam Injection?
Aztreonam-avibactam is an injectable antibiotic combination containing two active components:
- Aztreonam – a monobactam β-lactam antibiotic
- Avibactam – a non-β-lactam β-lactamase inhibitor
The combination has been developed to address specific resistance situations in which bacteria produce multiple β-lactamases.
A commonly referenced formulation contains aztreonam 1500 mg and avibactam 500 mg, providing a total of 2 g of the two active components. The U.S. prescribing information for EMBLAVEO, for example, describes a 2 g formulation containing 1.5 g aztreonam and 0.5 g avibactam.
The exact product, formulation, dosing regimen and approved indications depend on the applicable regulatory information.
Aztreonam + Avibactam Injection Composition
The two components perform different functions.
Aztreonam 1500 mg
Aztreonam is a monobactam antibiotic that interferes with bacterial cell-wall synthesis.
One important characteristic of aztreonam is its relative stability against hydrolysis by metallo-β-lactamases.
This property makes it scientifically interesting in the context of MBL-producing Gram-negative bacteria.
Avibactam 500 mg
Avibactam is a β-lactamase inhibitor rather than a conventional antibacterial antibiotic.
It inhibits several susceptible serine β-lactamases, including many class A and class C enzymes and selected class D enzymes.
However, avibactam does not directly inhibit metallo-β-lactamases such as NDM, VIM and IMP.
This distinction is essential when explaining how the combination works.
How Does Aztreonam and Avibactam Work Together?
The combination can be understood by looking at the resistance mechanisms separately.
Some bacteria producing MBLs can hydrolyze many β-lactam antibiotics.
Aztreonam is relatively stable against MBL-mediated hydrolysis. However, MBL-producing bacteria may also produce additional β-lactamases, such as ESBLs or AmpC enzymes, which can hydrolyze aztreonam.
This is where avibactam becomes important.
Avibactam inhibits several susceptible serine β-lactamases and can therefore protect aztreonam from those additional enzymes.
The simplified mechanism is:
MBL → can hydrolyze many β-lactam antibiotics
Aztreonam → relatively stable against MBL hydrolysis
ESBL/AmpC → can compromise aztreonam
Avibactam → inhibits several susceptible ESBL/AmpC enzymes
This complementary activity is the scientific basis for studying the combination against certain MBL-producing Gram-negative bacteria.
Recent literature describes aztreonam-avibactam as a mechanism-based approach involving MBL resistance, β-lactamase inhibition, susceptibility testing and clinical considerations.
Why Is This Combination Important in Antibiotic Resistance?
Not all β-lactamases behave in the same way.
Some enzymes can be inhibited by avibactam, while metallo-β-lactamases require a different consideration.
This means that simply identifying an organism as “β-lactam resistant” is not enough to understand whether aztreonam-avibactam may be active.
The underlying resistance mechanism and laboratory susceptibility result are important.
For example, an organism may produce:
- NDM
- ESBL
- AmpC
- Multiple β-lactamases
The combination of these mechanisms can influence the activity of available antibiotics.
Aztreonam Avibactam Injection and MBL-Producing Bacteria
Metallo-β-lactamases are enzymes that can inactivate many β-lactam antibiotics.
Important MBLs include:
- NDM
- VIM
- IMP
A key point is that avibactam does not directly inhibit these enzymes.
Instead, the rationale for combining avibactam with aztreonam is based on their complementary properties.
Aztreonam can remain relatively stable against MBL-mediated hydrolysis, while avibactam can inhibit susceptible serine β-lactamases that may be produced by the same bacterial isolate.
This mechanism has made aztreonam-avibactam an important area of research in antimicrobial resistance.
What Are Aztreonam Avibactam Injection Uses?
The clinical use of an aztreonam-avibactam formulation depends on the specific product, regulatory approval and clinical situation.
For example, the current U.S. labeling for EMBLAVEO includes use with metronidazole for adults with complicated intra-abdominal infections caused by susceptible organisms when there are limited or no alternative treatment options.
More broadly, the combination is being studied and used in the context of difficult-to-treat Gram-negative infections, particularly where resistance mechanisms make conventional β-lactam options problematic.
The appropriate treatment decision depends on:
- Identified bacterial pathogen
- Antimicrobial susceptibility results
- Resistance mechanism
- Infection site
- Severity of infection
- Patient-specific factors
- Applicable clinical guidelines
Therefore, an Aztreonam Avibactam injection should not be described as a universal treatment for antibiotic-resistant infections.
Aztreonam 1500 mg + Avibactam 500 mg Injection
The 1500 mg + 500 mg combination is an important search term because it describes the quantities of the two active components.
The combination can be represented as:
| Component | Amount | Role |
|---|---|---|
| Aztreonam | 1500 mg | Antibacterial component |
| Avibactam | 500 mg | β-lactamase inhibitor |
| Total active components | 2000 mg | Combination |
For example, the official U.S. labeling for EMBLAVEO identifies a 2 g vial containing 1.5 g aztreonam and 0.5 g avibactam.
The actual administration method and dosing schedule should always follow the applicable product information and healthcare-professional guidance.
How Is the Injection Administered?
Aztreonam-avibactam products are administered intravenously in clinical settings.
Administration details can vary according to the specific product and approved indication.
For example, official product information describes preparation and administration by intravenous infusion rather than self-administration.
Healthcare professionals determine the appropriate dose, infusion schedule and duration based on the approved product information and individual patient factors.
Aztreonam Avibactam and Beta-Lactamase Inhibition
The role of avibactam is central to understanding the combination.
Bacteria can produce β-lactamase enzymes that hydrolyze β-lactam antibiotics.
Avibactam inhibits several susceptible β-lactamases, including many class A and class C enzymes.
However, it does not inhibit every β-lactamase.
In particular:
Avibactam does not directly inhibit MBLs.
This is why the mechanism of aztreonam-avibactam should be explained as a complementary combination, rather than describing avibactam as an MBL inhibitor.
Aztreonam + Avibactam and Antimicrobial Susceptibility
Susceptibility testing is important when considering antimicrobial therapy for resistant organisms.
Two bacterial isolates belonging to the same species can have different resistance mechanisms and susceptibility profiles.
Factors such as β-lactamase production, additional resistance mechanisms and bacterial genetics can affect antimicrobial activity.
Therefore, treatment decisions should not be based on the name of an antibiotic combination alone.
Culture results, susceptibility testing, clinical assessment and applicable treatment guidelines should be considered together.
Meblanios: Aztreonam 1500 mg + Avibactam 500 mg Injection
Meblanios is an Aztreonam + Avibactam injectable formulation developed by AIONIOS Pharma.
It contains:
- Aztreonam 1500 mg
- Avibactam 500 mg
Meblanios therefore belongs to the broader Aztreonam Avibactam injection category.
The two components have complementary functions: aztreonam provides antibacterial activity, while avibactam inhibits susceptible β-lactamases.
For product-specific information, healthcare professionals should refer to the applicable product information and clinical guidance.
Aztreonam Avibactam: Key Points at a Glance
- Aztreonam is a monobactam β-lactam antibiotic.
- Avibactam is a β-lactamase inhibitor.
- Aztreonam has relative stability against MBL-mediated hydrolysis.
- Avibactam inhibits several susceptible serine β-lactamases.
- Avibactam does not directly inhibit NDM, VIM or IMP.
- The combination is designed around complementary mechanisms.
- Susceptibility testing is important for resistant bacterial infections.
- Clinical use depends on the specific product, indication and patient.
- Meblanios contains aztreonam 1500 mg + avibactam 500 mg.
Frequently Asked Questions
What is Aztreonam + Avibactam injection?
It is an injectable combination containing aztreonam, a monobactam β-lactam antibiotic, and avibactam, a β-lactamase inhibitor.
What is the composition of Aztreonam Avibactam injection?
A commonly referenced formulation contains aztreonam 1500 mg and avibactam 500 mg. Product formulations can vary, so the applicable product information should be checked.
What are Aztreonam Avibactam injection uses?
Uses depend on the specific formulation, regulatory approval and clinical situation. The combination has an important role in the context of selected difficult-to-treat Gram-negative infections and resistance mechanisms.
Does Avibactam inhibit MBL?
No. Avibactam does not directly inhibit metallo-β-lactamases such as NDM, VIM and IMP.
Why are Aztreonam and Avibactam combined?
Aztreonam has relative stability against MBL-mediated hydrolysis, while avibactam inhibits several susceptible serine β-lactamases that can otherwise compromise aztreonam.
What is Aztreonam 1500 mg + Avibactam 500 mg?
It is a 2 g combination consisting of 1500 mg aztreonam and 500 mg avibactam. This composition is used in certain aztreonam-avibactam injectable formulations.
Conclusion
Aztreonam + Avibactam injection combines two agents with different but complementary functions. Aztreonam provides antibacterial activity and has relative stability against metallo-β-lactamase-mediated hydrolysis, while avibactam inhibits several susceptible serine β-lactamases.
The combination is particularly relevant when discussing complex β-lactam resistance and MBL-producing Gram-negative bacteria.
However, avibactam itself is not an MBL inhibitor. Its importance in this combination comes from inhibiting susceptible β-lactamases that may coexist with an MBL and otherwise compromise aztreonam.
For this reason, understanding the bacterial resistance mechanism and susceptibility profile is essential when evaluating aztreonam-avibactam in clinical practice.
Medical Disclaimer: This article is for educational purposes only and should not replace professional medical advice. Antibiotic selection, dosing and administration should be determined by qualified healthcare professionals using the applicable product information, microbiological results, susceptibility testing and clinical guidelines.